Wealth Enhancement Advisory Services, LLC Travere Therapeutics, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $49 Billion
- Q1 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 10,139 shares of TVTX stock, worth $217,075. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,139Holding current value
$217,075% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TVTX
# of Institutions
219Shares Held
92.7MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$164 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$158 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$107 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$106 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$91.2 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.37B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...